FRE.DE Stock Dips 0.36% on May 1 Ahead of Earnings Report

Fresenius SE & Co. KGaA (FRE.DE) traded lower on May 1, 2026, as the healthcare giant prepares for its earnings announcement. The stock fell 0.36% to €41.25 on the XETRA exchange, with volume reaching 1.69 million shares—well above the 980,000-share average. The company faces investor scrutiny as it reports Q1 2026 results on May 6. FRE.DE stock has declined 13.68% year-to-date, reflecting broader healthcare sector pressures. With a market cap of €23.2 billion and a P/E ratio of 15.17, the stock trades near its 50-day moving average of €45.59. Meyka AI’s analysis platform tracks real-time sentiment as traders await earnings guidance.

FRE.DE Stock Performance and Technical Setup

Fresenius SE & Co. KGaA shares opened at €40.97 and traded between €40.51 and €41.35 during the session. The stock remains under pressure, down 7.49% over the past month and 18.09% over six months. However, the three-year performance shows resilience with a 62.15% gain, indicating long-term recovery potential.

Technical Weakness Signals Caution

The relative strength index (RSI) sits at 34.94, signaling oversold conditions. The MACD histogram shows -0.14, suggesting bearish momentum. The Stochastic oscillator at 22.52% reinforces weakness, while the Williams %R at -74.85 indicates extreme selling pressure. These technical indicators suggest the stock may be due for a bounce, though earnings clarity is needed first.

Earnings Spotlight: May 6 Results Expected

Fresenius will report Q1 2026 earnings on May 6 at 15:30 UTC. Analysts project earnings per share of €0.2542 and revenue of €6.82 billion for the quarter. The company’s trailing twelve-month EPS stands at €2.72, with a net profit margin of 5.53%.

Key Metrics Under Review

The healthcare provider operates four segments: Fresenius Medical Care (dialysis), Fresenius Kabi (IV drugs and nutrition), Fresenius Helios (hospitals), and Fresenius Vamed (facility management). Recent earnings coverage highlights the company’s diversified revenue streams across dialysis, pharmaceuticals, and hospital operations. Operating cash flow per share reached €4.57, while free cash flow per share was €2.07, showing solid cash generation despite revenue headwinds.

Valuation and Market Sentiment Analysis

FRE.DE trades at a P/E ratio of 15.17, below the healthcare sector average of 28.97, suggesting potential undervaluation. The price-to-sales ratio of 1.02 and price-to-book ratio of 1.22 indicate reasonable valuations relative to peers. The dividend yield stands at 2.42%, offering income support for long-term holders.

Market Sentiment and Trading Activity

Volume surged to 1.72 million shares, representing 172% of the 30-day average. This elevated activity reflects pre-earnings positioning. The stock’s 52-week range spans €39.99 to €52.96, placing current levels near the lower end. Track FRE.DE on Meyka for real-time updates and analyst sentiment shifts. Short interest declined 33.4% in April, suggesting reduced bearish bets and potential support building.

Financial Health and Growth Outlook

Fresenius maintains a debt-to-equity ratio of 0.62, indicating moderate leverage. The current ratio of 1.32 shows adequate liquidity for operations. However, net income growth declined 42.7% over three years, reflecting operational challenges in the dialysis and hospital segments.

Meyka AI Rating and Forecast

Meyka AI rates FRE.DE with a grade of B, suggesting a neutral stance. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects €60.70 for year-end 2026, implying 47% upside from current levels. The five-year forecast reaches €109.75, indicating long-term recovery potential. These grades and forecasts are not guaranteed and we are not financial advisors.

Final Thoughts

Fresenius faces a critical earnings test on May 6. The stock trades near technical support with oversold indicators suggesting potential reversal. At a P/E of 15.17 and 2.42% dividend yield, it appears undervalued versus healthcare peers at 28.97 P/E. However, three-year revenue and earnings declines require careful attention to Q1 guidance. Investors should await earnings results before making portfolio decisions. Management commentary on cost control and margin expansion will be key to determining the company’s recovery trajectory.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.